Your session is about to expire
← Back to Search
Radiation Therapy
1 for Huntington's Disease
Phase 1
Waitlist Available
Led By Ken Nedd, M.D.
Research Sponsored by GAAD Medical Research Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* People with HD
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.
Eligible Conditions
- Huntington's Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Find a Location
Who is running the clinical trial?
GAAD Medical Research Institute Inc.Lead Sponsor
21 Previous Clinical Trials
90 Total Patients Enrolled
Ken Nedd, M.D.Principal InvestigatorGAAD Medical Research Institute Inc.
19 Previous Clinical Trials
88 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger